Skip to Content

The Medical Letter on Drugs and Therapeutics
Objective, peer-reviewed evaluations of new FDA-approved drugs, and new information on previously approved drugs.
April 14, 2014 (Issue 1440)
  • Tasimelteon (Hetlioz) for Non-24-Hour Sleep-Wake Disorder
  • Avanafil (Stendra) for Erectile Dysfunction
  • Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms and Prevention of Osteoporosis
Treatment Guidelines from The Medical Letter
Unbiased reviews of drug classes used to treat common disorders. Includes the doses, adverse effects and the recommendations of expert reviewers.
April 2014 (Issue 140)
  • H2-RECEPTOR ANTAGONISTS (H2RAs) — Currently available H2RAs are listed in Table 1. These drugs inhibit the action of histamine at the H2-receptor of the gastric parietal cell, decreasing basal acid secretion and, to a lesser degree, food-stimulated acid secretion. All H2RAs are about... [more]
  • Drugs for Hypertension
  • Adult Immunizations